SEC Form 4 · accession 0001415889-16-007383
Vistagen Therapeutics, Inc. · VTGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon S Saxe
Director
Period of report
Nov 9, 2016
Accepted (ET)
Nov 10, 2016 · 8:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411685
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.80 | Nov 9, 2016 | A | 25,000 | A | — | Nov 9, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Options vest monthly over a period of three years commencing November 9, 2016.